Plogosertib

SKU: orb1738081

Description

Plogosertib (CYC140) is a potent, selective, and orally bioavailable ATP-competitive inhibitor of PLK1 (IC50=3 nM). It demonstrates robust antiproliferative effects in vitro and has shown promising antitumor activity in vivo, supporting its research use in both solid and hematological cancer models.

Research Area

Cell Biology

Key Properties

• CAS Number: 1137212-79-3
• MW: 616.797
• Purity: 99.85%
• Formula: C₃₄H₄₈N₈O₃
• SMILES: O=C1C2(CN(C=3C(N1C)=CN=C(NC4=C(OC)C=C(C(N[C@@H]5CC[C@H](CC5)N6CCN(C)CC6)=O)C=C4)N3)C7CCCC7)CC2
• Target: PLK

Bioactivity

• Target IC50:
  PLK1:3 nM|PLK2:149 nM|PLK3:393 nM
• In Vivo:
  In the HL60 promyelocytic leukemia xenograft model, Plogosertib (40, 54, 67 mg/kg, qd 5/2/5; oral administration) inhibited tumor growth (>87%) without significant loss in body weight.
• In Vitro:
  In KYSE-410 cells, Plogosertib (0, 0.07, 0.15, 0.3, 0.6, 1.25 μM; 72 hours) inhibits cell proliferation in a concentration-dependent manner.

Storage & Handling

• Storage: keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CYC 140, CYC140, CYC-140, AC 220, AC 010220, AC-220, AC010220, AC-010220, AC010220.2HCl, PLK1, Plogosertib, Quizartinib, Quizartinib dihydrochloride, Quizartinib HCl

Compound Identifiers

PubChem CID

42640739